Payment overview · 2025
General Payments
$54.05
3 reported records · 3 companies
Healthcare provider profile · identity verified
Eugene Douglas Larsen, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PRICE, UT · NPI 1447513221
Verified facts
What the public records show
CMS Open Payments records show Eugene Douglas Larsen, DO received $54.05 in general payments during 2025 across 3 reported records.
Collegium Pharmaceutical, Inc. accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.98 | 37.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.45 | 32.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.62 | 30.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $54.05 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 308 | 78 |
| Lisinopril | Lisinopril | 284 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 65 |
| Omeprazole | Omeprazole | 247 | 66 |
| Glipizide Er | Glipizide | 230 | 57 |
| Gabapentin | Gabapentin | 221 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 45 |
| Furosemide | Furosemide | 172 | 37 |
| Losartan Potassium | Losartan Potassium | 167 | 45 |
| Metformin Hcl | Metformin Hcl | 158 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 38 |
| Sertraline Hcl | Sertraline Hcl | 141 | 30 |
| Trazodone Hcl | Trazodone Hcl | 139 | 35 |
| Celecoxib | Celecoxib | 135 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 27 |
| Xarelto | Rivaroxaban | 125 | 25 |
| Tramadol Hcl | Tramadol Hcl | 114 | 32 |
| Montelukast Sodium | Montelukast Sodium | 113 | 35 |
| Alprazolam | Alprazolam | 108 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 32 |
| Spironolactone | Spironolactone | 98 | 24 |
| Prednisone | Prednisone | 88 | 36 |
| Metformin Hcl Er | Metformin Hcl | 86 | 21 |
| Simvastatin | Simvastatin | 86 | 27 |
| Potassium Chloride | Potassium Chloride | 85 | 24 |
| Allopurinol | Allopurinol | 84 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 16 |
| Carvedilol | Carvedilol | 80 | 20 |
| Pregabalin | Pregabalin | 77 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 16 |
| Eliquis | Apixaban | 72 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 16 |
| Ozempic | Semaglutide | 70 | 11 |
| Januvia | Sitagliptin Phosphate | 69 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 28 |
| Alendronate Sodium | Alendronate Sodium | 68 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 13 |
| Meloxicam | Meloxicam | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 12 |
| Warfarin Sodium | Warfarin Sodium | 55 | 11 |
| Azithromycin | Azithromycin | 54 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 13 |
| Baclofen | Baclofen | 43 | 16 |
| Famotidine | Famotidine | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Cefdinir | Cefdinir | 42 | 36 |
| Bumetanide | Bumetanide | 41 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 33 |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Naproxen | Naproxen | 31 | 14 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Droplet Insulin Syringe | Syrge-Ndl,ins 0.5 Ml Half Mark | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Guanfacine Hcl | Guanfacine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54.05 · 3 records | Collegium Pharmaceutical, Inc. | BREZTRI, Belbuca, Senza | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error